Danazol
(Synonyms: 达那唑) 目录号 : GC10785An androgen receptor agonist
Cas No.:17230-88-5
Sample solution is provided at 25 µL, 10mM.
Danazol showed weak androgenic effects.
Danazol is a derivative of testosterone and ethisterone. An androgen is any natural or synthetic agent stimulating or controling the development and maintenance of male characteristics by binding to androgen receptors. This includes the activity of the primary male sex organs and development of male secondary sex characteristics.
In vitro: Previous study found that danazol as low as 1 micrometer could suppress LH-stimulated testosterone and androstenedione production in cultured Leydig cells. The addition of danazol to a preparation of testicular microsomes elicited a type I cytochrome P-450 binding spectrum. Danazol could inhibit progesterone and 17alpha-hydroxy-progesterone binding to microsomal P-450 [1].
In vivo: The purpose of a previous study was to examine the role of androgen and estrogen receptors in danazol suppression of luteinizing hormone (LH) in the rat. The estrogen receptor antagonist, LY 156758, partially antagonized the suppressed levels of LH after administration of danazol to ovariectomized rats. In contrast, the androgen receptor antagonist, flutamide, had no effect on suppressed LH levels after danazol treatment, but did partially reverse the inhibition of LH 24 hr after danazol administration to ovariectomized rats [2].
Clinical trial: Danazol was administered to patients with advanced prostate cancer for periods ranging from 3 days to 18 weeks. There were no objective remissions, but three patients had objectively stable disease with complete pain control for periods ranging 15-18 weeks. Seven patients experienced tumor flare reactions, one requiring withdrawal of treatment and one resulting in rapid clinical deterioration and death. Four other patients died within 3 weeks [3].
References:
[1] Barbieri RL, Canick JA, Ryan KJ. Danazol inhibits steroidogenesis in the rat testis in vitro. Endocrinology. 1977 Dec;101(6):1676-82.
[2] Snyder BW, Beecham GD, Winneker RC. Danazol suppression of luteinizing hormone in the rat: evidence for mediation by both androgen and estrogen receptors. Proc Soc Exp Biol Med. 1990 May;194(1):54-7.
[3] Cole RM, Raghavan D, Caterson I, Teriana N, Pearson B, Boulas J, Rosen M. Danazol treatment of advanced prostate cancer: clinical and hormonal effects. Prostate. 1986;9(1):15-20.
Cas No. | 17230-88-5 | SDF | |
别名 | 达那唑 | ||
化学名 | pregna-2,4-dien-20-yno[2,3-d]isoxazol-17α-ol | ||
Canonical SMILES | O[C@@]1(C#C)CC[C@@]2([H])[C@]3([H])CCC4=CC5=C(C=NO5)C[C@]4(C)[C@@]3([H])CC[C@@]21C | ||
分子式 | C22H27NO2 | 分子量 | 337.5 |
溶解度 | ≥ 11.05 mg/mL in DMSO, ≥ 14.84 mg/mL in EtOH with ultrasonic | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.963 mL | 14.8148 mL | 29.6296 mL |
5 mM | 0.5926 mL | 2.963 mL | 5.9259 mL |
10 mM | 0.2963 mL | 1.4815 mL | 2.963 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet